POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

被引：6

作者：

Golan, Talia

Oh, Do-Youn

Reni, Michele

Macarulla, Teresa Mercade

Tortora, Giampaolo

Hall, Michael J.

Reinacher-Schick, Anke C.

Borg, Christophe

Hochhauser, Daniel

Walter, Thomas

Hochster, Howard S.

Baker, Nigel

Locker, Gershon Y.

Kindler, Hedy L.

机构：

[1] Sheba Med Ctr, Oncol Inst, Tel Hashomer, Israel

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Hosp San Raffaele, Milan, Italy

[4] Vall Hebron Univ Hosp HUVH, Barcelona, Spain

[5] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[6] Med Sch, Verona, Italy

[7] Univ Hosp, Verona, Italy

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Klinikum Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[10] Hop Jean Minjoz, Besancon, France

[11] UCL, UCL Canc Inst, London, England

[12] Hop Edouard Herriot, Lyon, France

[13] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS4152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4152

引用

页数：2

共 50 条

[31] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
Tutt, Andrew Nicholas James
Kaufman, Bella
Gelber, Richard D.
Mc Fadden, Eleanor
Goessl, Carsten Dietrich
Viale, Giuseppe
Arahmani, Amal
Fumagalli, Debora
Azim, Hatem Abdel
Wu, Wenting
Grocholewicz, Anna
Costantino, Joseph P.
Rastogi, Priya
Garber, Judy Ellen
Geyer, Charles E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Hammel, P.
Kindler, H. L.
Reni, M.
Van Cutsem, E.
Macarulla Mercade, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Joo, S.
Yoo, H. K.
Patel, N.
Golan, T.
ANNALS OF ONCOLOGY, 2019, 30 : 254 - 255
[33] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
Tutt, A.
Kaufman, B.
Garber, J.
Gelber, R.
McFadden, E.
Goessl, C.
Viale, G.
Geyer, C.
Zardavas, D.
Arahmani, A.
Fumagalli, D.
De Azambuja, E.
Ponde, N.
Herbolsheimer, P.
Wu, W.
Constantino, J.
Rastogi, P.
ANNALS OF ONCOLOGY, 2017, 28
[34] A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)
Martha E. Teke
Areeba Saif
Carrie E. Ryan
Stephanie C. Lux
Jonathan M. Hernandez
Kim A. Reiss
Annals of Surgical Oncology, 2022, 29 : 5375 - 5376
[35] A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)
Teke, Martha E.
Saif, Areeba
Ryan, Carrie E.
Lux, Stephanie C.
Hernandez, Jonathan M.
Reiss, Kim A.
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (09) : 5375 - 5376
[36] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Arnold, Dirk
Hammel, Pascal
Golan, Talia
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Algul, Hana
O'reilly, Eileen M.
Sharan, Kanu
Ou, Xiaoling
Cui, Karen
Locker, Gershon Y.
Kindler, Hedy L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 91 - 92
[37] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Hammel, P.
Golan, T.
Reni, M.
Van Cutsem, E.
Macarulla Mercade, T.
Hall, M.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
Sharan, K.
Ou, X.
Cui, K. Y.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1137 - S1137
[38] Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
Friedlander, Michael
Moore, Kathleen N.
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Lisyanskaya, Alla Sergeevna
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana N.
Oza, Amit M.
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William Hampton
Lowe, Elizabeth S.
Bloomfield, Ralph
Disilvestro, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Golan, Talia
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui Karen
Schlienger, Katia
Locker, Gershon Y.
Kindler, Hedy L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[40] POLO: Long-Term Safety and Tolerability of Olaparib for Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer
Kindler, H. L.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J.
Hochhauser, D.
Oh, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Locker, G. Y.
Arnold, D.
PANCREAS, 2021, 50 (07) : 1071 - 1071

← 1 2 3 4 5 →